-
Shanghai Cell Therapy Group Partners with Nantong Federation for Comprehensive Health Services Platform
•
Shanghai Cell Therapy Group has entered into a partnership with the Nantong Federation of Industry and Commerce, aiming to leverage their respective advantageous resources to create a comprehensive medical service platform. The collaboration will provide a range of health services, including high-end medical care, cell health, early tumor screening, and…
-
Huadong Medicine’s Subsidiary Perfect mRNA Biotechnology Partners with Yoltech Therapeutics
•
China-based Huadong Medicine Co., Ltd (SHE: 000963) subsidiary, Hangzhou Perfect mRNA Biotechnology Co., Ltd, has entered into a strategic partnership with compatriot firm Yoltech Therapeutics Co., Ltd. The collaboration aims to advance the development of gene editing products, mRNA drugs, and related services in both domestic and international markets. Focus…
-
Merck Appoints Marc Horn as China Unit President, Succeeding Allan Gabor
•
Germany-based Merck (NYSE: MRK) has announced the appointment of Marc Horn as its China unit president, effective as of January 1, 2024. Horn will take over from Allan Gabor, who is set to retire on December 31, 2023. In his new role, Horn will be responsible for formulating Merck’s development…
-
Sinocelltech Group Launches Biosimilar Version of AbbVie’s Humira in China
•
China-based Sinocelltech Group Ltd (SHA: 688520) has officially commercialized its biosimilar version of AbbVie’s (NYSE: ABBV) Humira (adalimumab), marking a significant milestone in the Chinese biosimilar market. The company has delivered the first batch of the biosimilar product, achieving commercialization in less than two weeks following regulatory approval. Humira’s Global…
-
Grand Pharmaceutical Initiates Phase II STARBURST Study for TLX250-CDx in Indication Expansion
•
China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced the first patient dosing in the indication expansion Phase II STARBURST study for its TLX250-CDx (89Zr-DFO-girentuximab). The imaging agent is licensed from Australia-based Telix Pharmaceuticals Ltd (ASX: TLX) in a 2020 deal valued at up to USD 225 million. The 2020…
-
Novlead Biotech Secures RMB 100 Million in Series B+ Financing for Nitric Oxide Therapy Innovations
•
Novlead Biotech, a specialist in nitric oxide gas detection and treatment based in Nanjing, has successfully completed a Series B+ financing round, raising RMB 100 million (USD 14 million). The round was led by Costone Asset Management, with significant contributions from Guanghua Holding, JYTH Investment, Lilly Asia ventures, and 3E…
-
Guangdong Zhongsheng Pharmaceutical Plans to Raise RMB 600 Million via Private Placement
•
China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) is poised to raise RMB 600 million (USD 84 million) through a private placement of 38,969,401 shares, priced at RMB 15.36 per share. This strategic move aims to bolster the company’s financial position and support its expansion plans. Focus on Core Business…
-
Shanghai Pharmaceuticals’ SPH3127 for Hypertension Gets MNPA Review Acceptance
•
China-based Shanghai Pharmaceuticals Holding Co., Ltd (SHA: 601607) has announced that the National Medical Products Administration (MNPA) has accepted a market approval filing for its SPH3127, a Category 1 drug co-developed with Japan-based Mitsubishi Tanabe Pharma Corporation. The intended indication for this novel drug is hypertension. SPH3127: A Novel Oral…
-
United Imaging Healthcare Acquires Stake in Apactron for High-End Particle Therapy Technology
•
Shanghai-based United Imaging Healthcare (UIH, SHA: 688271) has announced an investment of RMB 45 million (USD 6.3 million) to acquire a 4.7% stake in Shanghai Apactron Particle Equipment Co., Ltd., a company specializing in high-end particle therapy technology. This strategic deal is aimed at leveraging Apactron’s expertise in proton therapy…
-
Sequanta Technologies Partners with DarkJade Sciences to Establish Organoid Bank and Glioma Project
•
Sequanta Technologies, a leading multi-omics research and clinical service provider based in Shanghai, has announced a partnership with DarkJade Sciences, a renowned organoid specialist based in Beijing. The collaboration aims to leverage the respective strengths of both companies to establish an organoid bank, with the first project focusing on glioma…
-
Insilico Medicine Partners with ShanghaiTech University for Tumor Drug R&D Advancement
•
China-based AI-powered drug discovery firm Insilico Medicine has struck a partnership with ShanghaiTech University’s iHuman institute to bolster the research and development of tumor drugs with novel targets. This collaboration aims to leverage Insilico’s generative AI platform and ShanghaiTech’s expertise in structural biology to advance drug discovery. Leveraging AI for…
-
WinHealth Pharma Receives NMPA Approval for Glycerol Phenylbutyrate for Urea Cycle Disorders
•
China-based Hong Kong WinHealth Pharma Group Ltd has announced receiving market approval from the National Medical Products Administration (NMPA) for its glycerol phenylbutyrate, a drug used as a long-term treatment for patients with urea cycle disorders (UCDs). This approval specifically targets patients who cannot achieve disease control through protein intake…
-
Nanjing Leads Biolabs Receives FDA IND Approval for LBL-033 Phase I/II Clinical Trial
•
China-based Nanjing Leads Biolabs Co., Ltd has revealed that it has received Investigational New Drug (IND) approval from the US Food and Drug Administration (FDA) to initiate a Phase I/II clinical trial for its pipeline candidate, LBL-033. This anti-MUC16/CD3 bispecific antibody (BsAb) is set to be investigated as a potential…
-
AstraZeneca Weighs Spinning Off China Business to Shield Against Geopolitical Tensions
•
According to a report from the UK newspaper The Financial Times (FT), AstraZeneca (AZ, NASDAQ: AZN) has drafted plans to spin off its China business as a separate entity. Citing “three people familiar with the talks,” the UK-based pharmaceutical giant is said to have begun discussing the idea with bankers…
-
TG ImmunoPharma Receives FDA Approval for Phase I Clinical Study of TGI-6 Bispecific Antibody
•
China-based TG ImmunoPharma Co., Ltd has announced that it has received approval from the US Food and Drug Administration (FDA) to conduct a Phase I clinical study for its bispecific antibody (BsAb), TGI-6. This development marks a significant step forward in the company’s efforts to bring innovative immunotherapies to patients…
-
IASO Bio Receives FDA IND Approval for IASO-782 for Autoimmune Disorders
•
China-based IASO Bio has announced that the US Food and Drug Administration (FDA) has approved an Investigational New Drug (IND) filing for its pipeline candidate, IASO-782. This injectable drug candidate will be assessed in US clinical trials for the treatment of various autoimmune hematological disorders, including primary immune thrombocytopenia (ITP)…
-
Adicon Holdings Ltd IPO: A Strategic Move for Growth in Diagnostics
•
Adicon Holdings Ltd (HKG: 9860), a China-based independent clinic laboratory (ICL) service provider, has successfully completed its initial public offering (IPO) of 33.2 million shares on the Hong Kong Stock Exchange. The shares were priced at HKD 12.32 (USD 1.58) each, with net proceeds expected to reach HKD 83.9 million…
-
Acotec Scientific Holdings and Boston Scientific Group plc Sign MOU to Broaden Collaboration
•
China-based Acotec Scientific Holdings Ltd (HKG: 6669) has announced a memorandum of understanding (MoU) with US firm Boston Scientific Group plc (BSG, NYSE: BSX), signaling their intention to explore collaboration in multiple fields, including research and development (R&D), manufacturing, and marketing and sales. Financial details of the agreement were not…
-
Aosaikang Pharmaceutical’s ASKB589 Shows Promising Results in Solid Tumor Treatment Study
•
Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755) has revealed the latest results from a Phase I/II study for its Category 1 biologic product candidate ASKB589, which is being assessed as a treatment for solid tumors. The findings were presented at the 15th International Gastric Cancer Association (IGCA) meeting, highlighting the…
-
Jiangsu Hengrui Medicine Cancels Licensing Agreement with Mabworks Citing Market Changes
•
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced its decision to cancel a licensing agreement with compatriot firm Mabworks, along with a related equity investment deal, due to changes in the market landscape. This move signifies that Hengrui Pharmaceuticals will no longer hold exclusive commercialization rights to Mabworks’…
